Findings

What do systematic reviews say?

21 questions · 21 findings · 1 reviews

No studies found 15 · 71.4%GRADE not reported 0 · 0%Very low 0 · 0%Low 3 · 14.3%Moderate 3 · 14.3%High 0 · 0%

Number of ocular adverse events at the longest · people with primary open‐angle glaucoma or ocular hypertension

1 finding from 1 review

Rho kinase inhibitor for primary open‐angle glaucoma and ocular hypertension 2022 · Cochrane Headline outcomes only
no estimate extracted
4 studies · 1286 participants
Low